Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16600
Title: A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation
Austin Authors: Sood, Siddharth ;Haifer, Craig;Yu, Lijia;Pavlovic, Julie ;Churilov, Leonid ;Gow, Paul J ;Jones, Robert M ;Angus, Peter W ;Visvanathan, Kumar;Testro, Adam G 
Affiliation: Liver Transplant Unit Victoria, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
Department of Gastroenterology & Hepatology, University of Melbourne, Royal Melbourne Hospital, Melbourne, Victoria, Australia
Innate Immune Laboratory, University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia
Florey Department of Neuroscience and Mental Health, Austin Health, Melbourne, Victoria, Australia
Issue Date: Apr-2017
metadata.dc.date: 2017-01-30
Publication information: Liver Transplantation 2017; 23(4): 487-497
Abstract: Balancing immunosuppression after liver transplant is difficult, with clinical events common. We investigate whether a novel immune biomarker based on a laboratory platform with widespread availability that measures interferon gamma (IFNγ) after stimulation with a lyophilized ball containing an adaptive and innate immune stimulant can predict events following transplantation. 75 adult transplant recipients were prospectively monitored in a blinded, observational study. 55/75 (73.3%) patients experienced a total 89 clinical events. Most events occurred within the first month. Low week 1 (W1) results were significantly associated with risk of early infection (AUROC 0.74, p=0.008). IFNγ≤1.30IU/mL (LR+ 1.93, sensitivity 71.4%, specificity 63.0%) was associated with the highest risk for infection with minimal rejection risk. Nearly half the cohort (27/60, 45.0%) expressed IFNγ≤1.30IU/mL. Moreover, an elevated W1 result was significantly associated with the risk of rejection within the first month post-transplant (AUROC 0.77, p=0.002), but no episodes of infection. On multivariate logistic regression, IFNγ≥4.49IU/mL (OR 4.75) may be an independent predictor of rejection (p=0.05). CONCLUSION: Low IFNγ suggesting over-suppression is associated with infections, while high IFNγ indicating under-suppression is associated with rejection. This assay offers the potential to allow individualisation and optimisation of immunosuppression that could fundamentally alter the way patients are managed following transplantation. This article is protected by copyright. All rights reserved.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16600
DOI: 10.1002/lt.24730
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28133934
Type: Journal Article
Subjects: Infection
Biomarker
Immunosuppression
Interferon gamma
Rejection
Appears in Collections:Journal articles

Show full item record

Page view(s)

8
checked on Feb 27, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.